Definition
What is Endocrine Disruptors?
Chemicals that interfere with hormone systems, driving EU and US evaluation, identification criteria, and restriction programmes across product types.
Chemicals that interfere with hormone systems, driving EU and US evaluation, identification criteria, and restriction programmes across product types.
Foresight tracks Endocrine Disruptors developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
25% above the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
25 May 2026, 18:23
Source-backed regulatory and guidance signals tracked by Foresight, with the newest developments first.
ECHA Concludes REACH CoRAP Evaluations for Butanone and N-[4-[(9,10-Dihydro-4-Hydroxy-9,10-Dioxo-1-Anthryl)Amino]Phenyl]Acetamide
ECHA and the Swedish and Belgian authorities have now concluded REACH CoRAP substance evaluations for Butanone and N-[4-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1-anthryl)amino]phenyl]acetamide, with Member State conclusion documents available. These conclusions clarify how current data address concerns such as suspected reproductive toxicity and endocrine disruption and will guide whether further EU risk management is needed, so registrants and downstream users should review the findings and track any follow-on proposals.
California OEHHA Schedules June 2026 DARTIC Meeting on p,pʹ-Bisphenol Chemicals
California’s OEHHA has scheduled a 18 June 2026 meeting of its Developmental and Reproductive Toxicant Identification Committee to review updated hazard-identification materials on p,pʹ-bisphenol chemicals as part of the Proposition 65 listing process. This signals that bisphenol-based chemistries remain under active regulatory scrutiny, and companies with exposure to these materials in products reaching California should prepare for potential future Proposition 65 warning, substitution, or reformulation obligations if new listings proceed.
EU Commission Postpones Expiry of Medetomidine Approval for PT 21 Biocidal Products to 31 December 2026
In May 2026 the European Commission extended the EU approval of the biocidal active substance medetomidine for product-type 21 uses under the Biocidal Products Regulation until 31 December 2026. This extension avoids a near-term regulatory gap for antifouling products while signalling ongoing scrutiny of medetomidine’s endocrine-disrupting profile and the need to prepare for a future renewal or non-renewal decision.
California OEHHA Convenes DARTIC Meeting on p,pʹ-Bisphenol Hazard Identification (18 June 2026)
California OEHHA has scheduled a 18 June 2026 DARTIC meeting to review an updated proposal for hazard identification materials on a broad group of p,pʹ-bisphenol chemicals under Proposition 65, based on extensive developmental and reproductive toxicity evidence. While no listing decisions will be taken at this stage, the process signals likely 2027 listing consideration for multiple bisphenol analogues, so companies using these chemistries should start mapping relevant substances, uses, and potential exposure pathways in California.
EU Extends Medetomidine PT21 Biocidal Approval To 31 December 2026
The European Commission has extended the EU approval of the biocidal active substance medetomidine (product-type 21) until 31 December 2026 while renewal discussions continue. This keeps existing antifouling products using medetomidine on the market under unchanged conditions for an additional six months but signals that a stricter decision could follow once its endocrine-disruptor status is fully evaluated.
Commission Implementing Decision (EU) 2026/1089 Postpones Medetomidine PT 21 Biocidal Approval Expiry To 31 December 2026
The European Commission has adopted Implementing Decision (EU) 2026/1089, extending EU approval of the biocidal active substance medetomidine (product-type 21) until 31 December 2026 while renewal under the Biocidal Products Regulation continues. This short extension prevents a regulatory gap but, given medetomidine’s classification as having endocrine-disrupting properties, companies using it in PT 21 products should prepare for a potentially more restrictive renewal decision and plan product and supply strategies accordingly.
Slovenian Consumer Association Finds Bisphenols and Other Contaminants in Kitchen Towels
In May 2026 the Slovenian Consumer Association published independent lab tests on 13 paper kitchen towel brands, finding bisphenols and microbiological contamination in some recycled-fibre products and deeming at least one towel unsuitable for direct food contact. These results highlight higher risk profiles for certain recycled paper kitchen towels and may prompt manufacturers and retailers to tighten control of recycled fibre streams and anticipate pressure for stricter limits on bisphenols and hygiene in paper-based food-contact materials.
Environmental Science & Technology Perspective Reviews PFAS Toxicity Evidence And Human Health Risks
A new peer-reviewed Perspective in Environmental Science & Technology consolidates epidemiological and toxicological evidence that PFAS exposure is linked to cancer, metabolic, immune, reproductive, developmental, and endocrine effects, directly challenging myths that PFAS health risks are uncertain or unproven. This strengthens the scientific basis regulators and companies rely on when setting PFAS limits and phase-out strategies, signalling continued momentum toward stricter, class-based PFAS controls across jurisdictions.
Spain NGO Report Highlights Pesticide Residues and EU Food and Feed Omnibus Risks
Ecologistas en Acción’s 2026 “Directo a tus hormonas” report uses Spain’s 2024 official pesticide residue monitoring data to show widespread contamination of common foods, including high use of endocrine-disrupting and PFAS pesticides and frequent multiple residues. These findings, combined with criticism of the EU Food and Feed Omnibus proposal and persistent use of non-authorised and candidate-for-substitution substances, signal rising regulatory and reputational risk around pesticide use, residue limits, and food import strategies for Spanish and EU food supply chains.
EU NGOs Comment On CLP Transfer ATP For EDC, PBT And vPvB Classifications
In April 2026, NGOs EEB and PAN Europe submitted comments on the EU CLP “transfer ATP” proposal to move existing endocrine disruptor and PBT/vPvB classifications for pesticides and biocides into Annex VI. They call for a shorter six-month transition period and for specific active substances to be (re)included, signalling stakeholder pressure to accelerate and broaden harmonised hazard communication under CLP, REACH, BPR and PPP.
EFSA Concludes Peer Review of Proquinazid Pesticide Risk Assessment
EFSA has completed its peer review of the fungicide proquinazid under the EU plant protection products framework, concluding that it meets EU endocrine disruptor criteria for humans and leaving several consumer and environmental risk assessments unresolved. This sharply increases regulatory risk for the substance’s EU renewal, signalling potential non-renewal or tight restrictions and prompting manufacturers and agricultural users to reassess dependence on proquinazid, mitigation options, and alternative fungicides.
Portugal Comments on CLP Transfer ATP Harmonised Classifications
Portugal has filed detailed comments on the EU draft CLP Annex VI ‘Transfer ATP’, seeking multiple corrections to harmonised classifications for tributyltin compounds, nonylphenols and their ethoxylates, HBCDD, PFHpA salts, difethialone, quinoxyfen, cholecalciferol and related entries. If adopted, these revisions could change PBT/vPvB and endocrine disruptor flags, concentration limits and mixture-classification rules under CLP, so companies using these substances should monitor the final ATP text and prepare for potential label and safety data sheet updates.
Germany Supports 18‑Month Transition Period for CLP Annex VI Transfer ATP
Germany’s chemicals authority has formally called for an 18‑month transition period in the upcoming CLP Annex VI “transfer” delegated act moving ED/PBT/vPvB listings from REACH, BPR and PPPR into CLP. If the Commission accepts this position, companies handling affected substances would gain extra time to adjust classifications, labelling and safety data sheets, easing implementation planning while final timelines still depend on the adopted text.
Swedish Chemicals Agency Comments on CLP Annex VI Transfer ATPs for D5, D6 and RP-HP
In April 2026 the Swedish Chemicals Agency submitted comments on the EU’s CLP Annex VI transfer ATPs, supporting removal of certain PBT and ED ENV hazard classes from harmonised entries for D5, D6 and RP-HP where these classifications rely on impurities. This signals a regulatory focus on classifying the underlying impurity substances instead, while ensuring that mixtures containing D4 or 4-HPbl above harmonised concentration limits remain subject to hazard-based classification obligations.
DUCC Submits Feedback to CARACAL-57 on CLP Annex VI Transfer ATP, Urging Minimum 18-Month Transition
In April 2026, DUCC submitted feedback to the EU CARACAL-57 meeting on the planned CLP Annex VI transfer ATP, urging alignment with standard ATP practice and at least an 18-month transition period, with longer timelines for some newly listed SVHCs. If this approach is accepted, downstream users across multiple sectors could gain more predictable lead time to update safety documents, labels, formulations and certifications before stricter harmonised classifications take effect.
EU: Bayer AG Submits Comments on Proposed CLP ED HH1 Classification of Metribuzin
Bayer AG has filed technical comments contesting the proposed CLP ED HH1 classification of metribuzin in the EU, arguing that thyroid effects seen in animal studies are not relevant to humans and that, at most, an ED HH2 classification should apply following a targeted harmonised CLP process. If regulators adjust metribuzin’s endocrine disruptor classification in response, the resulting CLP labelling and potential risk management expectations for metribuzin-based plant protection products could change materially, so companies using this active substance should closely track the final classification outcome and plan for both stricter and more moderate scenarios.
U.S. Study Highlights PFAS and Other Contaminants in Drinking Water, Calls for Continuous Regulatory Reform
Environmental Health News highlights a 13 May 2026 open‑access article in Environmental Science and Pollution Research, "Addressing contaminants of emerging concern in the United States public water systems," which evaluates how all 50 U.S. states address PFAS and other contaminants of emerging concern (CECs) in public drinking water.[^2^] The study finds that only a small group of states have strong, multi‑contaminant frameworks, while most focus narrowly on a few regulated PFAS and leave many pharmaceuticals, agrochemicals, microplastics and personal‑care product ingredients weakly regulated or unregulated, reinforcing calls for more intentional, continuous reform of U.S. drinking water and chemical policy, including class‑based CEC regulation and stronger support for small and disadvantaged systems.[^1^][^2^]
Austria (AT CA) Supports Inclusion of RP‑HP in CLP Annex VI (Transfer ATP)
Austria’s chemicals authority has formally backed including the SVHC reaction products RP‑HP in Annex VI of the CLP Regulation via the forthcoming Transfer ATP, arguing there is no legal basis to exclude it simply because its hazards are driven by the 4‑HPbl constituent. This strengthens the signal that ED/PBT/vPvB Candidate List substances like RP‑HP will move into harmonised CLP entries, foreshadowing future EU‑wide labelling and risk‑management obligations once the delegated act is adopted.
PARC Advances Integrative Risk Assessment and Provides Rapid Response Data to EFSA
In May 2026, the EU Partnership for the Assessment of Risks from Chemicals (PARC) announced new integrative mixture risk-assessment deliverables, expanded training for regulators, and Rapid Response data used by EFSA in its assessment of Alternaria toxins in food and feed. These scientific outputs do not create new legal obligations but signal a stronger evidence base and tools that could shape future EU chemical and food-safety policies, especially around mixture exposures, human biomonitoring and natural toxins.
EU / ECHA Delays Expected CLH Dossier Submission for 4,4'-Isopropylidenedi-2,6-xylol to December 2026
ECHA has updated its harmonised classification and labelling (CLH) registry so that Denmark’s CLH dossier on 4,4'-isopropylidenedi-2,6-xylol, proposed as an endocrine disruptor for human health and the environment, is now expected to be submitted in December 2026 rather than mid-2026. This pushes back the likely timing of any EU-wide harmonised classification while confirming sustained regulatory scrutiny of the substance, giving companies more time to prepare for potential future labelling, risk management, and substitution decisions.
These are just a few of the most recent Endocrine Disruptors alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialTopic context
Definition
Chemicals that interfere with hormone systems, driving EU and US evaluation, identification criteria, and restriction programmes across product types.
Industry relevance
Endocrine Disruptors developments can change product scope, supplier expectations, market access, reporting duties, and risk ownership. Foresight tracks the signals early so teams can respond before obligations become urgent.
Foresight tracking
Foresight monitors official sources, extracts structured regulatory intelligence, and maps alerts to a customer's products, substances, markets, and priorities so teams see the relevant signal with source evidence for review.
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at